OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.
Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share.
Without disrupting legacy sales - CEO Shai...
Hapbee (HAPB) Adds 18 New Signal Blends in Major Expansion of Its Digital Wellness...
Hapbee now comes bundled with "lifetime blends" and offers an all-access subscription option.
VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ - Hapbee Technologies,...
OMNIQ (OMQS) to Begin Trading on NASDAQ
100% Here, 100% There, Pretty Soon it all Adds up. Our Sixth Client to Graduate to NASDAQ.
Yes, some...
With Hapbee (HAPBF) Who Needs, Drugs, Caffeine or Nicotine?
Record 1 Million Hours of Mood Stimulation Served by Hapbee (HAPBF).
TRADING AT THE LOWER END OF...
Discontinuing Coverage on Dalrada (DFCO).
We Are Temporarily Discontinuing Coverage on Dalrada Financial.
Great little company and we're up 400%. But with the market...
Aphex BioCleanse Further Expands Distribution Channels.
Aphex BioCleanse Systems Announces Partnership With Bifulco Consulting Group to Expand Distribution Channels
PITTSFORD, N.Y., May 20, 2021...
Two of Our $5.00 Watch List Stocks Double, in Like Just Five Months!
Added to the Watch List in November, OMNIQ (OMQS) and Galaxy Digital (GLXY) Shine like a Pretty Penny, with OMNIQ Doubling...
OMNIQ (OMQS) $10.00, Announces Record $25 Million in New Orders, 100% Growth in AI-Based...
OMNIQ Announces Q4 2020 Revenue, up 12% YoY achieving $13 Million in Q4 Revenue; Growth Accelerates in Q1 2021 with a...
Interview: Scott Donnell from Hapbee (HAPB, HAPBF) on Wall Street Reporter.
Transcript follows.
Hapbee CEO Live with the Wall Street Reporter
Listen in as Hapbee CEO...
Investment Manager With $1 Billion in Assets Under Management, Buys 300 Hapbee (HAPB) Head...
Things that make you go mmmm.
Randy Eisenman is co-founder and managing partner of Satori Capital with more than...
Latest article
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
